The QualityStocks Daily Monday, September 12th, 2022

Today's Top 3 Investment Newsletters

CannabisNewsWire(INM) $18.7800 +70.42%

CryptoCurrencyWire(BLQC) $0.3700 +42.31%

MarketClub Analysis(IBRX) $5.6100 +20.91%

The QualityStocks Daily Stock List

Clear Channel Outdoor Holdings (CCO)

MarketBeat, Streetwise Reports, TradersPro, MarketClub Analysis, The Street, InvestorPlace, Daily Trade Alert, Marketbeat.com, StreetInsider, Wealth Insider Alert, Trades Of The Day, Stockhouse, AllPennyStocks, SmarTrend Newsletters, Zacks, Super Stock Investor, Super Stock Picker, Top Pros' Top Picks, StockMarketWatch, One Hot Stock, StockOodles, Market Intelligence Center Alert, Jason Bond, The Bull Report, Investing Daily, FNNO Newsletters, BUYINS.NET and QualityStocks reported earlier on Clear Channel Outdoor Holdings (CCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Clear Channel Outdoor Holdings Inc. (NYSE: CCO) (FRA: C7C1) is a holding company that is focused on owning, operating and selling advertising displays internationally and in the U.S.

The firm is based in San Antonio, Texas and was incorporated in 1995. It serves consumers in the United States and generates the majority of its revenue from outdoor advertising in America. Prior to changing its name in August 2005, the firm was called Eller Media Company.

It operates using 2 segments: The International outdoor advertising segment and America’s outdoor advertising segment. The former segment has its operations mainly in Latin America, Asia and Europe while the latter segment’s operations are mainly in the U.S. Their products include transit advertising, which advertises transit systems and different types of vehicles; street furniture displays like freestanding units, information kiosks and advertising on bus shelters and billboards, including posters and bulletins, in digital and traditional formats.

The company also offers a public bicycle rental program, which provides for rent bicycles to various municipalities, maintenance, cleaning and street furniture equipment services, and creative and production services. In addition, it serves telecommunications, entertainment, food products and food as well as retail sectors. Through its subsidiaries, it also offers out-of-home display advertising like mobile advertising services, walls capes, panels, posters and digital billboards.

The company is set to grow exponentially after it breaks even in the near future. This will make it more profitable and is bound to bring in more investors, which will boost share prices.

Clear Channel Outdoor Holdings (CCO), closed Monday's trading session at $1.92, up 10.3448%, on 2,393,972 volume. The average volume for the last 3 months is 1.736M and the stock's 52-week low/high is $0.9069/$4.10.

Palatin Technologies (PTN)

MarketBeat, StreetInsider, BUYINS.NET, StockMarketWatch, Greenbackers, The Sandman, QualityStocks, Zacks, Kiplinger Today, StockEgg, The Street, CoolPennyStocks, Penny Invest, Jason Bond, TopPennyStockMovers, BullRally, PennyTrader Publisher, HotOTC, Otc stock alert, MadPennyStocks, InvestorPlace, DrStockPick, CRWEWallStreet, CRWEFinance, BestOtc, FeedBlitz, Stock Rich, WealthMakers, Trading Concepts, Tiny Gems, StockRich, Stockpalooza, PennyInvest, Stock Stars, Marketbeat.com, Stock Fortune Teller, PennyToBuck, PennyStockVille, PennyOmega, Barchart, Mega Penny Stock Pick and StockHotTips reported earlier on Palatin Technologies (PTN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Palatin Technologies Inc. (NYSE American: PTN) (FRA: PTNA) is focused on the development of receptor-specific therapeutics for treating different ailments.

The firm has its headquarters in Cranbury, New Jersey and was incorporated in 1986, on November 21st by John K.A. Prendergast and Carl Spana. The firm serves consumers in the United States.

The biopharmaceutical company develops medicines based off of molecules which modulate activity of the natriuretic and melanocortin peptide receptor systems. The latter receptor system has effects on immune system responses, inflammation, sexual function, metabolism and food intake. On the other hand, the former receptor system regulates tissue homeostasis and cardiovascular functions.

The enterprise’s product candidates are targeted, receptor-specific peptide therapeutics for treating illnesses with unmet medical needs which have commercial potential. They include an oral selective melanocortin receptor (MCr) agonist peptide dubbed PL8177, which has concluded a phase 1 trial evaluating its effectiveness in treating inflammatory bowel diseases, and a MCr agonist known as Vyleesi, for treating premenopausal women with hypoactive sexual desire disorder. It also develops a peptide melanocortin agonist active at different MCrs dubbed PL9643, for anti-inflammatory ocular indications. In addition to this, the enterprise develops melanocortin peptides indicated for diabetic retinopathy treatment; a natriuretic peptide receptor-A (NPR)-A and NPR-binder for the treatment of fibrotic and cardiovascular ailments known as PL5028; and aNPR-A agonist dubbed PL3994, for cardiovascular indications.

The firm recently released its latest financial results of 2021 which show increases in revenues. It is currently focused the advancement of its melanocortin agonist programs.

Palatin Technologies (PTN), closed Monday's trading session at $7.8, up 15.0442%, on 408,849 volume. The average volume for the last 3 months is 407,996 and the stock's 52-week low/high is $4.00/$24.00.

Finance of America Companies (FOA)

MarketBeat, QualityStocks, Trades Of The Day, StocksEarning and Daily Trade Alert reported earlier on Finance of America Companies (FOA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Finance of America Companies Inc. (NYSE: FOA) is a consumer lending platform which connects investors with borrowers.

The firm has its headquarters in Irving, Texas and was incorporated in 2013. It was formed as a result of a merger between Replay Acquisition and Finance of America Equity Capital. The firm serves consumers in the United States.

The company’s vertically integrated lending and services platform seamlessly connects investors with borrowers. Its objective is to accelerate its growth, innovate new products and services, and become a one stop shop to meet all the financial needs of consumers. The company operates through the following segments: Lender services, Commercial originations, Reverse originations, Mortgage originations and Portfolio management. The company’s subsidiaries include Finance of America Reverse LLC and Finance of America Mortgage LLC.

The enterprise has designed a distribution network which enables customers to interact using their preferred method, be it digitally, telephonically, through a broker or in person. It offers a diverse selection of lending products and services, with a focus on investing and loan origination. The enterprise’s products include business purpose loans to residential real estate investors; reverse mortgage loans and traditional mortgage loans to consumers; commercial loans, home improvement loans and home loans.

The company’s Reverse LLC subsidiary recently launched a new website, which will help improve how the company engages with a wide range of its consumers as well as how it showcases its suite of flexible and modern alternative financing solutions. This move will not only strengthen Finance of America’s brand and bring in more opportunities, but also boost its growth, which will be good for its shareholders.

Finance of America Companies (FOA), closed Monday's trading session at $1.6, up 15.1079%, on 522,062 volume. The average volume for the last 3 months is 521,445 and the stock's 52-week low/high is $1.20/$5.99.

SelectQuote Inc. (SLQT)

Schaeffer's, StreetInsider, InvestorPlace, The Online Investor, Zacks, Trades Of The Day, Top Pros' Top Picks, StocksEarning, MarketBeat and Cabot Wealth reported earlier on SelectQuote Inc. (SLQT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SelectQuote Inc. (NYSE: SLQT) (FRA: 6SJA) is an insurance agency that operates as a technology-enabled, direct-to-consumer distribution platform, engaged in the sale of various insurance products and healthcare services.

The firm has its headquarters in Overland Park, Kansas and was incorporated in 1999, on August 18th. It operates as part of the insurance brokers industry, under the financial services sector. The firm serves consumers in the United States, with a focus on those in the state of Kansas.

The company was founded with the goal of helping customers protect the individuals and things they value most. It provides consumers with a convenient and transparent venue to shop for a range of complex insurance policies from a curated panel of insurance carriers. The company’s proprietary technology enables them to find for consumers the right coverage with the right carrier at a good price, in minutes.

The enterprise operates through the SelectQuote Auto & Home, Life and Senior business lines. The Life business line is engaged in the provision of unbiased comparison shopping for life insurance and ancillary products including juvenile insurance, term life, accidental death, final expense and guaranteed issue. Its Auto and Home offering provides an unbiased comparison shopping platform for home, auto and specialty insurance lines. On the other hand, the enterprise’s Senior offering provides unbiased comparison shopping for Medicare Supplement and Medicare Advantage insurance plans, as well as severe illness, hearing, vision, dental and prescription drug plans and products.

The company recently released its latest financial results, with its CEO noting that they remain focused on optimizing its core healthcare and senior services. This will help improve its returns and create value for its shareholders, while also bolstering its growth.

SelectQuote Inc. (SLQT), closed Monday's trading session at $1.32, off by 7.6923%, on 2,905,984 volume. The average volume for the last 3 months is 2.877M and the stock's 52-week low/high is $0.95/$15.03.

Whole Earth Brands (FREE)

OTCtipReporter, Gryphon Digest, SmallCapInvestorDaily, PennyStockScholar, OTCPicks, SmallCap Network, Stock Analyzer, Greenbackers, Kiplinger Today, QualityStocks, PennyStockLocks.com, MarketBeat, Penny Stocks VIP, BUYINS.NET, Value Penny Stocks, PennyStockSpy, Equity Observer, StreetInsider, StreetAuthority Daily, The Street, StockRunway, Michael Stone, OTCBB Journal, StocksImpossible, ProfitableTrading, 007 Stock Chat, StockRockandRoll, Growing Stocks Reports, StockMister, ResearchOTC, Jet-Life Penny Stocks, SmallCapVoice, SmarTrend Newsletters, Daily Wealth, FreeRealTime, HoleinOneStocks.net, HotStockProfits, BullFreak, InvestorPlace, Broad Street, CRWEFinance, Hit and Run Candle Sticks, Stock Shock and Awe, WiseAlerts, Whisper from Wall Street, Wallstreetlivechat, Trades Of The Day, TopPennyStockMovers, Pennybuster, StockOodles, Jason Bond, Shiznit Stocks, Zacks, PennyPro, Penny Stock General, Penny Dreamers, Otcstockexchange and The Online Investor reported earlier on Whole Earth Brands (FREE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Whole Earth Brands Inc. (NASDAQ: FREE) is a global food company that is focused on the manufacture of low/zero sugar and calorie sweeteners, as well as reduced-sugar products.

The firm has its headquarters in Chicago, Illinois and was incorporated in 2018. It operates as part of the packaged foods industry, under the consumer cyclical sector. The firm serves consumers across the globe, with a focus on the United States.

The company has a platform of branded ingredients and products, focused on the consumer transition toward clean label products and natural alternatives. It operates through the Middle East & Africa, Europe, Latin America, Asia-Pacific and North American geographical segments.

The enterprise operates through the Branded CPG and Flavors & Ingredients segments. The Branded CPG (consumer packaged goods) segment is focused on building a branded portfolio serving consumers who seek low-calorie, zero-calorie, no-sugar added, natural and plant-based products. This segment provides a range of sweetener formulations under the Equal, Canderek, Swerve, Wholesome, Pure Via and Whole Earth brands, to address local price points and consumer preferences. On the other hand, the Flavors and Ingredients segment offers functional ingredients with product mouth-feel modification, flavoring enhancement, moisturizing, flavor or aftertaste masking and skin soothing characteristics. This segment also provides licorice-derived products for use in food, confectionery, beverage, tobacco, personal care, pharmaceutical and cosmetic product applications.

The firm recently announced its latest financial results, which show a growth in its consolidated revenue, as well in its Branded CPG and Flavors segments. It remains focused on strengthening its portfolio and fielding for opportunities that will drive its overall growth.

Whole Earth Brands (FREE), closed Monday's trading session at $4.98, off by 1.3861%, on 210,525 volume. The average volume for the last 3 months is 209,784 and the stock's 52-week low/high is $4.545/$13.065.

Sidus Space (SIDU)

MarketClub Analysis and INO Market Report reported earlier on Sidus Space (SIDU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sidus Space Inc. (NASDAQ: SIDU) is a space-as-a-service firm that is focused on designing, manufacturing, launching and collecting data on commercial satellites.

The firm has its headquarters in Merritt Island, Florida and was incorporated in 2012, on July 17th by Carol M. Craig. Prior to its name change, the firm was known as Craig Technologies Aerospace Solutions. It operates as part of the aerospace and defense industry, under the industrials sector. The firm operates as a Craig Technical Consulting Inc. subsidiary and serves consumers around the globe.

The enterprise’s services include satellite manufacturing; space-based data services and analytics; low earth orbit microsatellite; precision manufacturing, assembling and testing; payload integrations; launch and support services; precision computer numerical control machining and fabrication; 3D composite and metal printing; wire cable harness fabrication; Swiss screw machining; and satellite deployment and microgravity research and testing services, as well as services associated with electronic and electric assemblies. The enterprise also provides hardware solutions, which include an external flight test platform for the development, testing and flying experiments. This is in addition to delivering a space station integrated kinetic launcher for orbital payload systems; and advanced electronics, materials and hardware on the international space station. It serves the commercial space, defense, aerospace, underwater marine and other government and commercial clients.

The company recently announced that it had entered into a launch agreement with SpaceX for live launches. This move will not only bring in additional revenues and investments into the company, but also open it up to new growth opportunities that will aid in the creation of significant value for its shareholders.

Sidus Space (SIDU), closed Monday's trading session at $2.62, off by 2.2388%, on 535,591 volume. The average volume for the last 3 months is 535,591 and the stock's 52-week low/high is $1.2601/$29.70.

Ballantyne Strong (BTN)

Wall Street Resources, MarketBeat, Marketbeat.com, Ballantyne Strong, StockMarketWatch, SmallCapVoice, MarketClub Analysis, InvestorPlace, QualityStocks, SmarTrend Newsletters, StreetAuthority Daily, The Street, Trade of the Week, Zacks, StockOodles, StreetInsider, Penny Invest, TradersPro, TradingAuthority Daily, Dividend Opportunities, Daily Market Beat and StockEgg reported earlier on Ballantyne Strong (BTN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ballantyne Strong Inc. (NYSE American: BTN) (FRA: BFQ) is a holding firm that is involved in a range of business activities, including advertising, digital signage, cinema products and services, as well as insurance, reinsurance and investment management services.

The firm has its headquarters in Charlotte, North Carolina and was incorporated in 1932 by Robert Scott Ballantyne. It operates as part of the leisure industry, under the consumer cyclical sector. The firm serves consumers around the globe.

The company owns several subsidiaries and investments, with its assets including both partially-owned and wholly owned businesses and investments in private and public companies. Its subsidiaries include Strong Studios, Strong Technical Services and Strong/MDI Screen Systems Inc.

The enterprise manufactures and distributes customized screen support systems and projection screens directly as well as through 3rd party integrators and distributors. It also offers technical support services to the cinema exhibition industry, schools, theme parks, museums and other entertainment-related markets. In addition to this, the enterprise provides technical services, which include network support services, after-sale maintenance and digital projection equipment installation, directly to theater owners and other entertainment-related markets, as well as via value added reseller networks and dealers. Further, it supports and distributes third party products, which include sound systems, menu boards, servers, library management systems and digital projectors.

The firm recently announced its latest financial results, which show increases in its revenues. It remains focused on expanding its offering around the globe and executing against its strategy to drive long-term value for its stakeholders.

Ballantyne Strong (BTN), closed Monday's trading session at $2.34, off by 0.847458%, on 14,820 volume. The average volume for the last 3 months is 14,794 and the stock's 52-week low/high is $2.06/$3.46.

Nexgel Inc. (NXGL)

We reported earlier on Nexgel Inc. (NXGL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nexgel Inc. (NASDAQ: NXGL) is a company involved in manufacturing a range of hydrogel solutions.

The firm has its headquarters in Langhorne, Pennsylvania. Prior to its name change in November 2019, the firm was known as AquaMed Technologies Inc. It operates as part of the medical instruments and supplies industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on those in the United States

The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. It has been developing and manufacturing cross-linked hydrogels for more than twenty years now. With help from its strategic partners, the company has formulated over 200 different combinations to bring natural ingredients to gentle skin patches which can be worn for extended periods with little to no irritation. The company generates revenue from contract manufacturing.

The enterprise manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, which are used in transdermal drug delivery, wound care, medical diagnostics and cosmetics. It markets its gels under the LumaGel Beauty and MedaGel brand names. The products sold under the LumaGel Beauty brand primarily relate to cosmetic and beauty solutions, like skin and wrinkle cream applications. On the other hand, the products sold under the MedaGel brand mainly related to over-the-counter remedy solutions, like pain and blister applications.

The firm recently released its latest financial results, with its CEO noting that they increased investments into research and development for the long-term growth opportunities of the business. It remains focused on expanding its hydrogel line which will facilitate the introduction of new products to the market and generate additional revenues.

Nexgel Inc. (NXGL), closed Monday's trading session at $1.88, up 2.7266%, on 138,481 volume. The average volume for the last 3 months is 138,481 and the stock's 52-week low/high is $1.3629/$4.66.

Bright Green Corporation (BGXX)

The Stock Dork and QualityStocks reported earlier on Bright Green Corporation (BGXX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bright Green (NASDAQ: BGXX) is one of the few companies selected by the U.S. government to grow, manufacture and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. The company recently announced its entry into a securities purchase agreement with institutional investors to purchase 9,523,810 shares of common stock and warrants to purchase 9,523,810 shares of common stock, at a purchase price of $1.05 per share and accompanying warrant. The company expects approximately $10.0 million in gross proceeds from the offering, which, subject to the satisfaction of certain customary conditions, is expected to close on Sept. 12, 2022. EF Hutton, division of Benchmark Investments LLC, is acting as exclusive placement agent for the offering.

To view the full press release, visit https://ibn.fm/FsDhu

About Bright Green Corporation

Bright Green is one of the very few companies selected by the U.S. government to grow, manufacture and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Bright Green’s conditional approval, based on already agreed terms from the U.S. Drug Enforcement Administration, positions the company to advance its vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.BrightGreen.us.

Bright Green Corporation (BGXX), closed Monday's trading session at $1.65, off by 1.1976%, on 1,029,577 volume. The average volume for the last 3 months is 999,899 and the stock's 52-week low/high is $1.00/$58.00.

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Penny Dreamers, InvestorPlace, CFN Media Group and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that it is presenting and participating via the on-demand session at the H.C. Wainwright 24th Annual Global Investment Conference taking place Sept. 12-14, 2022. Beginning Monday, Sept. 12, interested parties may access FSD Pharma’s on-demand presentation by visiting https://ibn.fm/mPBst, where it will be hosted for 90 days. In addition, the presentation and supporting materials will be available shortly thereafter on the FSD Pharma website within the “For Investors” section. “We are extremely motivated to develop and commercialize FSD Pharma’s portfolio of novel therapeutics and working with high quality institutional investors is instrumental in meeting our goals,” said Dr. Lakshmi Kotra, who serves as CEO of FSD Pharma’s wholly owned subsidiary Lucid Psycheceuticals. Dr. Kotra also provides development oversight for the complete FSD Pharma pipeline. “As one of the country’s premier annual conferences, we look forward to the H.C. Wainwright event to interact with the investment community and elucidate on the tremendous potential of our pipeline.”

To view the full press release, visit https://ibn.fm/dEpYK

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information, visit the company’s website at www.FSDPharma.com.

FSD Pharma Inc. (HUGE), closed Monday's trading session at $0.92, up 0.294342%, on 53,901 volume. The average volume for the last 3 months is 53,412 and the stock's 52-week low/high is $0.6947/$1.78.

HIVE Blockchain Technologies Ltd. (HIVE)

InvestorPlace, QualityStocks, MarketClub Analysis, MarketBeat, StreetInsider, StockMarketWatch, Marketbeat.com, Greenbackers, Hit and Run Candle Sticks, Barchart, Stock Market Watch, WealthMakers, StockOodles, StreetAuthority Daily, TopStockAnalysts, Wall Street Resources and smartOTC reported earlier on HIVE Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

When cryptocurrencies were first introduced, they promised to deliver low to zero transaction costs, unlimited withdrawals and purchases, fast transaction speeds, and enhanced security and privacy. These features set crypto apart from centralized currencies and attracted millions of users in just a few years. However, the anonymity, security and privacy offered by blockchain also drew in criminals who were looking for a way to move their ill-gotten gains away from the prying eyes of law enforcement.

A 2021 report by blockchain analysis firm Chainalysis revealed that criminals laundered a whopping $8.6 billion in cryptocurrency in 2021 alone. The report stated that criminals are transferring billions of dollars’ worth of cryptos to services that seemed to be tailor-made for money laundering, stating that law enforcement could deal a major blow to crypto-based crime by disrupting these services.

A Europol Report from January points to criminal networks with a flair for large-scale money laundering that have adopted cryptocurrencies and begun offering money-laundering services to other criminals.

During the 6th Global Conference on Criminal Finances and Cryptocurrencies hosted by Europol at The Hague, experts conceded that the proliferation of blockchain and crypto has “facilitated new forms of crime.” Speakers, who included representatives of European law enforcement, speakers and experts from major cryptocurrency analysis firms, said criminals are increasingly adopting crypto as it expands into “practically every nation and sector.”

Cryptos have been involved in match-fixing within sports, drug smuggling and, alarmingly, financing the acquisition, manufacture and possession as well as export of weapons of mass destruction. Even so, Europol believes that blockchain has “unique characteristics” that will allow law enforcement to investigate all forms of organized crime syndicates along with the money laundering networks they use to move their funds. Furthermore, blockchain will also make it possible to recover stolen money.

Addressing organized crime on blockchain will call for the right capacity and tools as well as cooperation, the report observed. Europol stated that regulators, law enforcement, the private sector and all the entities involved in combating crime are already working to address the rise of money laundering via blockchain. This includes recently passed legislation that would ensure cryptos are treated like other assets from a legal perspective.

More specifically, the new regulations will require that crypto exchanges collect and then store identifying data for people making cryptocurrency transactions and turn that data in to authorities conducting money-laundering investigations. This would allow authorities to make definitive strikes against criminal networks that have turned to blockchain to launder their money.

As law enforcement registers successes against criminal entities looking to exploit the strengths of blockchain technology, the entire industry, including companies such as HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE), is likely to enjoy widespread adoption as it cements its reputation as a technology that is here for everyone’s good.

HIVE Blockchain Technologies Ltd. (HIVE), closed Monday's trading session at $5.12, up 0.195695%, on 1,272,984 volume. The average volume for the last 3 months is 1.268M and the stock's 52-week low/high is $2.8201/$28.00.

Alliance Resource Partners L.P. (ARLP)

The Online Investor, Zacks, TradersPro, MarketBeat, The Street, Marketbeat.com, MarketClub Analysis, QualityStocks, InvestorPlace, TopStockAnalysts, Dividend Opportunities, TheStockAdvisor, The Wealth Report, The Motley Fool, Money Morning, StreetAuthority Daily, Market Intelligence Center Alert, BUYINS.NET, Investing Daily, Daily Wealth, Daily Trade Alert, Rick Saddler, Wealth Insider Alert, The Growth Stock Wire, Trading Concepts, TheOptionSpecialist, TheStockAdvisors, SmarTrend Newsletters, TraderPower, Top Pros' Top Picks, Daily Markets, Trades Of The Day, Eagle Financial Publications, FNNO Newsletters, Greenbackers, Insider Wealth Alert, Short Term Wealth, Investor Update, Leeb's Market Forecast, TheTradingReport, TheStreet Offers, Money and Markets, PoliticsAndMyPortfolio.com, StreetInsider and Investment U reported earlier on Alliance Resource Partners L.P. (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Russia-Ukraine war has had a domino effect on global coal demand that could significantly benefit coal exporting countries such as Australia. With Russia, which is one of the world’s largest coal suppliers, essentially booted out of the global coal market, Australia has seen its coal prices soar.

Before Russia invaded Ukraine, many European countries had began shutting down their coal-fired power plants in favor of cleaner energy sources. In the wake of Russia’s unprovoked invasion, plenty of countries condemned the attack and urged Russia to cease its war effort and withdraw from Ukraine.

Furthermore, western countries issued a series of economic sanctions against the country, such as cutting down on Russian energy imports to cripple its economy and halt Russia’s unprovoked invasion.

Russia, which is one of the top energy producers in the country, retaliated to these sanctions by cutting gas exports to the rest of Europe, plunging the region into an even deeper energy crisis. European countries were forced to fire up their coal power plants for energy generation despite pledging to move away from coal. And, although some countries turned to cheap Russian coal as a stopgap measure, an impending ban on coal from Russia means they will have to find other alternatives fast.

Australia, currently the fifth-largest producer and second-largest exporter of coal on the planet, has stepped in to fill the shoes left by Russia. Data compiled by OPIS shows that recently spot physical coal at the Newcastle port in Australia was priced at an all-time high of $436.71 per ton. This is almost three times more that the spot physical coal prices at the same time last year.

In addition, ICE Futures Europe reported a 5% price jump to $463.75 a ton for October Newcastle futures, the highest prices have been since January 2016. And benchmark coal prices in Europe have also soared to record highs due to uncertainty over Russian gas exports and predictions for increased coal demand.

High prices have also been fueled by expectations of weather disruptions at key Australia coal mines in the wake of a forecast that predicted heavy La Nina rains in late 2022 that have increased fears of a supply crunch. A note from Morgran Stanley analysts revealed that any “severe disruptions” to coal shipments from Australia could cause the price of high-calorific coal to skyrocket to untold highs. Heavy La Nina rains have impacted Australian coal mines in the past, with coal output from Queensland and New South Wales states being reduced by 20% to 30% during a 2010–2011 severe weather event.

The high prices Australian coal is enjoying on the world market are also benefiting other industry players such as Alliance Resource Partners L.P. (NASDAQ: ARLP) since buyers are scrambling to obtain coal from every source available before winter sets in and energy use hikes.

Alliance Resource Partners L.P. (ARLP), closed Monday's trading session at $25.36, up 0.078927%, on 831,206 volume. The average volume for the last 3 months is 827,930 and the stock's 52-week low/high is $8.63/$27.63.

The QualityStocks Company Corner

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has announced a private placement agreement with two healthcare-focused institutional investors. The agreement calls for the issuance and sale of 691,245 of INM common shares; the shares will be sold at a purchase price of $8.68 per share in a private placement priced according to Nasdaq guidelines. According to the announcement, InMed will also issue unregistered preferred investment options that will allow investors in the offering to purchase more than 1.3 million common shares. The company noted that it anticipates gross proceeds from the placement, which is expected to close on or about Sept. 13, 2022, to reach some $6 million. The company plans to use the funds gathered from the offering to continue its focus on pipeline development of its proprietary pharmaceutical drug candidates as well as advance manufacturing knowledge of cannabinoids and cannabinoid analogs and support intellectual property development and other commercial activities; the company may also use proceeds from the offering for general working capital purposes. The announcement also noted that any unregistered investment options issued in the offering will be exercisable upon issuance at an exercise price of $8.44 per share; the shares will expire seven years from the date of issuance. To view the full press release, visit https://ibn.fm/0PpIb

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Monday's trading session at $18.78, up 70.4174%, on 31,937,457 volume. The average volume for the last 3 months is 31.937M and the stock's 52-week low/high is $5.8225/$59.25.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

  • Consensus among autonomous vehicle experts increasingly lean in favor of implementing lidar solutions to promote AV safety
  • HD cameras only provide raw image data in 2D; lidar uses laser technology to determine exact distance and location of objects
  • Cepton produces state-of-the-art, intelligent, lidar-based applications for AV, ADAS, smart cities, connected spaces, and smart industrial applications
  • CPTN engaged with top 10 global automotive OEMs, including GM and Ford

Expert opinions concerning autonomous vehicle (“AV”) safety are leaning in favor of using lidar (light detection and ranging) technologies in addition to HD cameras, a positive development for Cepton (NASDAQ: CPTN), a developer of lidar-based solutions that help enable Advanced Driver Assistance Systems (“ADAS”), AVs, smart cities, connected spaces, and smart industrial applications.

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $1.78, up 4.0936%, on 269,840 volume. The average volume for the last 3 months is 265,288 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) has announced that it will be addressing attendees of the H.C. Wainwright 24th Global Investment Conference being held in New York from Sept. 12 to 14, 2022. The company’s CEO and Board Chair Ian Clifford will be providing a corporate update to conference attendees, as well as meeting with a series of registered investors, both in person and virtually. FuelPositive’s presentation, for which the main focus will be the company’s onsite, containerized green ammonia production system, is scheduled for Sept. 12 at 3 p.m. ET. Interested parties should visit https://ibn.fm/8F6kg to register for the conference and/or book a meeting with FuelPositive. The presentation will be recorded on video and posted to the conference and FuelPositive websites in the days following the event. To view the full press release, visit https://ibn.fm/aLDRE

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Monday's trading session at $0.12, up 0.755668%, on 156,501 volume. The average volume for the last 3 months is 156,501 and the stock's 52-week low/high is $0.09/$0.24.

Recent News

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF)

The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a company focused on developing enterprise-grade infrastructure to drive Bitcoin adoption, has operated on the Lightning Network (“LN”) since November 2021, amassing a capacity of over 30 BTC with more than 300 channels facilitating BTC transactions for micropayment users. “The Lightning Network has allowed users to complete payments using the layer 2 protocol quicker than traditional blockchain and even faster than some of the world’s leading institutions. Payments made using the LN offer faster settlement times, cheaper fees and higher levels of security than their centralized counterparts,” a recent article reads. “With the increased need for operational efficiency and transparency in financial payment systems, implementing cryptocurrency as a viable monetary solution appeals to developing and underdeveloped countries worldwide. LQwD is at the forefront of this movement, leveraging its Bitcoin assets to drive further adoption of the LN. With the assistance of its proprietary platform-as-a-service (‘PaaS’), users can send payments instantly, securely and inexpensively anywhere in the world.” To view the full article, visit https://ccw.fm/wJV2T

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.

Product

The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Monday's trading session at $0.0791, up 12.6781%, on 7,270 volume. The average volume for the last 3 months is 7,270 and the stock's 52-week low/high is $0.0602/$0.672.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

REZYFi, a cannabis mortgage bank, is positioned as one of the first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry. Led by a management team with more than 40 years’ experience in the mortgage and lending industry and leveraging other corporate strengths such as a network of independent brokers and proprietary technology, REZYFi services the needs of both traditional and non-traditional consumers and businesses. “Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year,” a recent article reads. “REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate, FHA and VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year… The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.” To view the full article, visit https://ibn.fm/Pn8mx

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.

Operations

REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.


Recent News

chart

American Cannabis Partners

The QualityStocks Daily Newsletter would like to spotlight American Cannabis Partners.

Decades of cannabis policing have significantly impacted society, especially among Black and Brown communities that were much more likely to be arrested and incarcerated for cannabis offenses despite similar use rates to White people. More than two decades after states first started legalizing cannabis, tens of thousands of people are still affected by cannabis convictions, either languishing in jail or failing to integrate into society due to their criminal records. For most cannabis reform activists, efforts to legalize the drug have had a major focus on social and criminal justice to help alleviate the damage done by the decades-long war on drugs. This has often been through provisions requiring social equity applicants to be given a leg up in their state cannabis industries as well as the expungement of prior cannabis records. Sealing and expunging prior cannabis offenses has been a talking point of most activists in the country as having a criminal record can have lifelong negative impacts on an individual. These moves on the criminal justice front complement the other benefits that come from legalization and allowing state-legal companies such as American Cannabis Partners to operate and provide jobs, pay taxes and boost the local economy.

American Cannabis Partners (ACP) is a multi-state cannabis company with 560,000 square feet of licensed canopy space for cultivation and one retail license. The company is nationally headquartered in Trinity County of Northern California’s Emerald Triangle.

ACP is focused on three complementary business segments: real estate, acquisition & development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with 30+ years of canna-business experience, ACP’s strategy is to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on Federal interstate commerce opportunities.

Through its current cultivation operations, ACP supplies approximately 80% of its whole flower products for manufacturing, distribution and retail licenses. With the remaining 20%, the company supplies its proprietary strains to select California distributors and its own Michigan retail location under its exclusive in-house brand, ZÜK.

History of American Cannabis Partners

In 2014, Stephen Jordan, President of ACP, took on the Director of Operations position for a U.S.-based company operating in the Jamaican cannabis space. Over the course of his three-year tenure in this role, Jordan developed a number of relationships that would help serve as the basis of American Cannabis Partners.

One such relationship was with Junior Gordon, a cultivation lead grower from Jamaica’s Westmoreland Parish. Jordan immediately saw the value of Gordon’s unique skillset and credentials, and Gordon recognized Jordan’s heartfelt vision of bringing Jamaican culture to the rapidly developing U.S. cannabis space.

Guided by that mission, ACP’s unchanging goal is to improve the lives of individuals through cannabis and business.

Current Operations

Since its founding in 2018, privately-owned American Cannabis Partners has established a foothold in two key U.S. cannabis markets – California and Michigan. In total, the company has acquired 12 cannabis licenses, including 20,000 sq. ft. of cultivation licenses in California and 540,000 sq. ft. of cultivation licenses & one retail license in Michigan.

ACP’s IP portfolio features three proprietary strains sold exclusively through the company’s wholly owned ZÜK brand, as well as proprietary data collection and mining systems supporting its cultivation and retail operations.

Plans for Expansion

American Cannabis Partners is pursuing additional growth in the cannabis sector through multiple planned initiatives. These include:

  • Submitting applications for additional cultivation licenses at the company’s Trinity County, California, location;
  • Planning land acquisition and project development strategies for expanding operations to its third U.S. state beginning in the second quarter of 2022; and
  • Planning land acquisition and project development strategies for expanding operations to its fourth U.S. state beginning in the second quarter of 2024.

ACP is currently exploring expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri and Massachusetts.

Management Team

Stephen Jordan is the CEO of American Cannabis Partners. He is focused on the first and last steps of legal cannabis – cultivation and retail. To date, Mr. Jordan has provided the company with ownership of 12 licenses, three proprietary cannabis strains and multiple real estate assets. His background in cannabis operations and financial strategies has guided American Cannabis Partners’ efforts to produce consistently high-quality product for both the medical and recreational segments. Mr. Jordan has operated under cultivation, manufacturing, distribution, medical research (Univ. of West Indies), retail and exportation licenses in multiple countries, further strengthening his network within the cannabis industry.

Gary Coltek is the company’s Chief Operating Officer. He has credentials based in the culinary, hospitality and sustainability industries spanning over 40 years, including taking three companies public. Mr. Coltek has held management positions internationally with Ritz Carlton, Four Seasons, Trump Hospitality, Phymatrix and International Oncology Network. For 17 years, he was the founding member and partner of a private boutique consulting firm. He is currently a guest speaker and visiting professor at universities in Israel, China, Italy, the Netherlands and Peru, covering topics that include culinary sustainability, sustainable cannabis farming, organic sustainable farming and cannabis clinical studies.

Scot C. Crow is the Lead Corporate Counsel for American Cannabis Partners. He has extensive experience in corporate mergers & acquisitions and tax law. His clients rely on him to advise them with respect to their complex financial transactions and provide outside general counsel. Mr. Crow provides his clients proactive advice with respect to sensitive management matters, litigation management, day to day transactional needs and objective assessments for the development of successful business strategies. His experience includes serving as lead counsel for numerous mergers & acquisitions, private equity investments, private offerings, venture capital financings, mezzanine debt offerings, divestures and other related transactions, with an emphasis in the legalized marijuana segment.

Jacob Frenkel is the company’s Lead Compliance Counsel. He is the current Chair of Dickinson Wright’s Government Investigations and Securities Enforcement Practice. Mr. Frenkel’s solutions-minded approach to issues has earned him a reputation as an aggressive, tenacious, creative and proactive defense lawyer and litigator. After 14 years as a Senior Counsel in the SEC’s Division of Enforcement, U.S. federal criminal prosecutor and New Orleans Assistant District Attorney, Mr. Frenkel has practiced in the private sector for 20 years. His unique mix of corporate transactional, litigation and investigations defense clients extend well beyond the cannabis industry and cover a wide range of industries worldwide.

Junior Gordon is the Director of Cultivation for American Cannabis Partners. With 30 years of international cannabis cultivation experience in both the Caribbean and United States, Mr. Gordon is recognized as one of the top growers in the world. His skills span both controlled indoor and large volume outdoor harvest programs, giving him proficiency in nursery, propagation and indoor & outdoor grow strategies. As a winner of High Times and other notable Cannabis Cups, his focus is on connecting the dots between propagation, soil, irrigation, planting, harvesting, curing, processing and inventory control, bringing Jamaican cannabis cultivation best practices to American Cannabis Partners’ operations.

Recent News

chart

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

After decades of cannabis criminalization and anti-cannabis propaganda, certain stereotypes about cannabis users have become entrenched in the public mind. The stereotypical image of a cannabis user as an apathetic “lazy stoner” who spends his days getting high, polishing off Doritos and generally contributing nothing to society is one example. Tons of people, especially older generations that grew up in the era of the drug war, tend to believe this stereotype. However, a new study has revealed that the stereotype of cannabis users as unmotivated and lazy is far from factual. Researchers found that there was no difference in reward-based behavior and apathy among people who used cannabis at least once a week and people who didn’t use cannabis at all. Furthermore, the researchers discovered that cannabis users tend to experience more pleasure than people who abstain from using cannabis. As more of these baseless stereotypes are disproved by science, the world is likely to see more people trying cannabis and even taking an additional step forward by growing their own plants using the handy micro gardens commercialized by companies such as Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Monday's trading session at $0.65, even for the day. The average volume for the last 3 months is 4,080 and the stock's 52-week low/high is $0.314/$1.87.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

  • Goldman Sachs’s yearly report on the global music industry expects music streaming revenues to reach $89.3 billion in 2030, with paid streaming contributing $55.6 billion and ad-funded streaming contributing $33.7 billion of the total
  • Friendable’s 360-degree artist platform offers independent music artists the tools they need to produce, distribute, and market their music while generating (and keeping) revenue
  • On average, artists lose 90% of streaming revenue to record labels, 10% to booking agents, and 15-20% of overall income to managers while feeling unsupported and controlled by these labels

The highly coveted yearly music industry update released by Goldman Sachs strives to answer the billion-dollar question – how much will the music industry be worth in 2030? The update suggests that global music streaming revenues will reach $89.3 billion in 2030, with paid streaming contributing $55.6 billion and ad-funded streaming contributing $33.7 billion. Goldman Sachs analyst Lisa Yang and a team of colleagues penned the company's report citing that the reduced increase in its projection numbers is driven by higher paid streaming annual revenue per user and ad-funded streaming assumptions. The decrease also includes the decline in physical sales (https://ibn.fm/hbiqv). On average, artists lose 90% of streaming revenue to record labels, 10% to booking agents, and 15-20% of overall income to managers. The fees are not the only problem; most artists feel a lack of support and a lack of control, in addition to their financially burdensome strict financial contracts. In the changing landscape of the music industry, labels must be willing to adapt, and Friendable’s (OTC: FDBL) 360-degree streaming artist platform offers the solution for them to do that.

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Monday's trading session at $0.0001, even for the day, on 55,696,469 volume. The average volume for the last 3 months is 43.081M and the stock's 52-week low/high is $0.000001/$0.0127.

Recent News

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

Osteosarcoma is a rare bone cancer that most often affects the long bones in the legs and arms. Although it occurs most often in young adults, older adults and younger children are also at risk of developing osteosarcoma. This type of bone cancer is often characterized by bone pain and swelling, with younger people usually experiencing these symptoms around the upper arms or knees. The National Organization for Rare Disorders estimates that some 750 to 1,000 individuals are diagnosed with the disease each year in the United States with some 450 of them being the age of 20. Furthermore, recent research has revealed that Black individuals aged 10 to 24 years old are more likely to develop osteosarcoma compared to other racial/ethnic groups. Research is also taking place with the aim of finding effective treatments for osteosarcoma. For example, QSAM Biosciences Inc. (OTCQB: QSAM) has a drug in clinical development targeting pediatric osteosarcoma. The success and eventual approval of this formulation could go a long way toward helping patients suffering from this debilitating condition.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.

CycloSam®

CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Monday's trading session at $5.4, off by 9.0909%, on 902 volume. The average volume for the last 3 months is 901 and the stock's 52-week low/high is $3.50/$19.60.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria’s Mexican patent “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Ingredients” joins the ranks of previously issued patents in Australia, India, Japan and the EU
  • The patent allows the company to provide value in gaining regulatory approval for its DehydraTECH(TM)-enabled CBD for multiple indications in the health and wellness field
  • Additional claims to Mexican patent #390001 include Alzheimer’s disease, Parkinson’s disease, schizophrenia, Human Immunodeficiency Virus (“HIV”) dementia, obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine addictions
  • The global market of CBD for health and wellness purposes was valued at $4.9 billion in 2021 and is expected to grow to $47.22 billion by 2028

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that the Company has received its 27th worldwide patent, granted in Mexico under registration #390001. The patent from Lexaria’s third patent family, “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents,” has already been issued in Australia, India, and Japan (https://cnw.fm/bsY27). The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $3.15, off by 0.630915%, on 25,176 volume. The average volume for the last 3 months is 25,026 and the stock's 52-week low/high is $1.85/$7.19.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

  • FingerMotion launched its mobile device protection service on July 15, 2022, banking on the transition to and the proliferation of 5G within the Chinese market
  • With the Chinese government targeting over 2 million 5G base stations by the end of the 2022 calendar year, FingerMotion is counting on consumers’ switch from 3G and 4G phones to 5G to grow its new product and market share as a whole
  • Martin Shen, FingerMotion’s CEO, is confident that this new direction by the company will not only sustain but also supersede the previous years’ performance, having posted a 12% gross margin growth in 2022, up from 9% in the 2021 financial year
  • He has reiterated that the company’s current revenue is “just the tip of the iceberg” and is confident that over the next 6-12 months, FingerMotion will achieve significant revenue growth

FingerMotion’s (NASDAQ: FNGR) latest offering, mobile device protection, launched on July 15, 2022, could not have come at a more opportune time. Mimicking Apple’s AppleCare service but specifically tailored for the Chinese market, FingerMotion sought to capitalize on a largely untapped market, previously limited to broken screen protection (https://ibn.fm/JIZUn). FingerMotion (NASDAQ: FNGR), a leader in mobile payment and recharge platform solutions in China, has consistently reinvented itself and adjusted to changing customer preferences. “Today, its goal remains to serve over a billion users in China and expand its model to other regional markets. However, its management understands that this will only be achieved by the company adjusting and improving its operations to address the changing market environment and evolving customer needs,” a recent article reads. “With every passing year, FingerMotion has gained experience in the market and from interacting with key partners in various sectors. It continues to leverage all this to improve its services and the value offered to consumers. This has allowed it to grow its list of offerings into four main areas: telecommunications products and services, SMS and MMS services, big data insights, and rich communication services (‘RCS’). Its latest addition, the device protection program, stems from FingerMotion recognizing a vast untapped market in China, valued at approximately $10.6 billion annually. It seeks to target over 1.2 billion mobile phone users in the country, most of whom do not have access to a device protection plan.” To view the full article, visit https://ibn.fm/3oFaH.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Monday's trading session at $0.700301, off by 7.8551%, on 83,124 volume. The average volume for the last 3 months is 82,570 and the stock's 52-week low/high is $0.70/$9.25.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

  • Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatment
  • The CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spans
  • Odyssey provides a portfolio of diverse technologies and related medical products to meet the unmet medical needs of concussion and TBI patients

Each year, medical costs in the United States for concussions total $20 billion ($400 billion worldwide). There is a significant unmet medical need for treatments for concussions in the medical landscape, with most diagnosed patients sent home with a standard of care involving rest, analgesics for headaches, and anti-depressants. Repeat concussions can lead to early dementia and Chronic Traumatic Encephalopathy (“CTE”), with the likelihood of athlete head injury recurrence totaling 75% (https://ibn.fm/z6bKU). Currently, there is no FDA-approved drug treatment for concussions, with the CDC noting that about 50% of people with traumatic brain injury (“TBI”) will experience decline in their daily lives or die within five years of their injury, while 57% will become moderately or severely disabled (https://ibn.fm/f5dvW). Odyssey Health (OTC: ODYY), a medical technology company focused on lifesaving medical products that offer technological and clinical advantages over current standards of care, is moving forward in its quest to meet the unmet needs of concussion patients. Recently, the company announced that its investigational agent PRV-002, a fully synthetic, nonnaturally occurring neurosteroid intended to treat concussion, was reported to be safe and well tolerated in a small cohort of volunteers. The company is currently in the process of selecting clinical sites and developing the Investigator’s Brochure for a Phase 2 trial (https://ibn.fm/e0DMX).

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Monday's trading session at $0.147, off by 0.675676%, on 37,040 volume. The average volume for the last 3 months is 37,040 and the stock's 52-week low/high is $0.11/$0.64.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.